Skip to main content
SpringerLink
Log in

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Bisphosphonates have been shown to attenuate ectopic calcification in experimental uremia. While they are known to reduce bone turnover, the effects on endochondral bone formation have not yet been addressed. To address this issue, we administered male Sprague-Dawley rats weekly subcutaneous injections of either vehicle or ibandronate (1.25 μg/kg body weight) for a total of 10 weeks. The rats were randomly allocated into one of four groups: (1) vehicle-treated, sham-operated rats; (2) ibandronate-treated, sham-operated rats; (3) vehicle-treated, 5/6 nephrectomized rats; (4) ibandronate-treated, 5/6 nephrectomized rats. Bones were double labeled with tetracycline and demeclocycline in vivo, and tibiae were removed for analysis. Weight gain was similar in all groups. Ibandronate reduced body length gain and tibial growth rate in the sham-operated animals but not in the rats showing chronic renal failure (CRF). The height of the proliferative zone of the epiphyseal growth plate was reduced in the ibandronate-treated controls and tended to be reduced in CRF rats. A significant correlation between tibial growth rate and height of the proliferative zone was observed. Mineral apposition rates were significantly reduced in ibandronate-treated, sham-operated rats and tended to be reduced in CRF rats. In conclusion, ibandronate interferes with tibial growth and bone mineralization in young rats with normal and reduced renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945–1953

    Article  CAS  PubMed  Google Scholar 

  2. Moe SM, Drueke T, Lameire N, Eknoyan G (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chron Kidney Dis 14:3–12

    Article  Google Scholar 

  3. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K (2004) Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 24:25–38

    Article  PubMed  Google Scholar 

  4. Kiela PR, Ghishan FK (2009) Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 89:7–14

    Article  CAS  PubMed  Google Scholar 

  5. Lund RJ, Davies MR, Brown AJ, Hruska KA (2004) Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 15:359–369

    Article  CAS  PubMed  Google Scholar 

  6. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H (2007) Vascular calcification and osteoporosis–from clinical observation towards molecular understanding. Osteoporos Int 18:251–259

    Article  CAS  PubMed  Google Scholar 

  7. Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9[Suppl 4]:3–13

    Article  CAS  PubMed  Google Scholar 

  8. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045

    Article  CAS  PubMed  Google Scholar 

  9. Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119[Suppl 2]:S150–S162

    Article  PubMed  Google Scholar 

  10. Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H (2005) Effect of etidronate on aortic calcification and bone metabolism in calcitoriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 99:89–94

    Article  CAS  PubMed  Google Scholar 

  11. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617–625

    Article  CAS  PubMed  Google Scholar 

  12. Neven EG, De Broe ME, D'Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582

    Article  CAS  PubMed  Google Scholar 

  13. Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824

    Article  CAS  PubMed  Google Scholar 

  14. Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915

    CAS  PubMed  Google Scholar 

  15. Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577–1583

    Article  CAS  PubMed  Google Scholar 

  16. Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538

    Article  CAS  PubMed  Google Scholar 

  17. Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45–53

    CAS  PubMed  Google Scholar 

  18. Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 5:174–181

    CAS  PubMed  Google Scholar 

  19. Haffner D, Hocher B, Müller D, Simon K, Konig K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U (2005) Systemic cardiovascular disease in uremic rats induced by 1, 25(OH)2D3. J Hypertens 23:1067–1075

    Article  CAS  PubMed  Google Scholar 

  20. Brkovic D, Seibel M, Juchem R, Linke J, Rohde D, Bauss F (2004) Effect of augmentation cystoplasty on bone metabolism in chronic uremic rats. J Urol 171:921–925

    Article  PubMed  Google Scholar 

  21. Brkovic D, Linke J, Jakse G, Bauss F (2005) Changes in bone structure after augmentation cystoplasty in chronic uraemic rats. BJU Int 95:1066–1070

    Article  PubMed  Google Scholar 

  22. Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox AG, Denton J, De Broe ME, D'Haese PC (2005) Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67:1830–1836

    Article  CAS  PubMed  Google Scholar 

  23. Donath K, Breuner G (1982) A method for the study of undecalcified bones and teeth with attached soft tissues. The Säge-Schliff (sawing and grinding) technique. J Oral Pathol 11:318–326

    Article  CAS  PubMed  Google Scholar 

  24. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610

    Article  CAS  PubMed  Google Scholar 

  25. Hunziker EB (1994) Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech 28:505–519

    Article  CAS  PubMed  Google Scholar 

  26. Eurell JA, Sterchi DL (1994) Microwaveable toluidine blue stain for surface staining of undecalcified bone sections. J Histotechnol 17:357–359

    Google Scholar 

  27. Cruz-Orive LM, Hunziker EB (1986) Stereology for anisotropic cells: application to growth cartilage. J Microsc 143:47–80

    CAS  PubMed  Google Scholar 

  28. Cobo A, Lopez JM, Carbajo E, Santos F, Alvarez J, Fernandez M, Weruaga A (1999) Growth plate cartilage formation and resorption are differentially depressed in growth retarded uremic rats. J Am Soc Nephrol 10:971–979

    CAS  PubMed  Google Scholar 

  29. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105

    Article  PubMed  Google Scholar 

  30. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119

    Article  CAS  PubMed  Google Scholar 

  31. Ishitani MB, Milliner DS, Kim DY, Bohorquez HE, Heimbach JK, Sheedy PF 2nd, Morgenstern BZ, Gloor JM, Murphy JG, McBane RD, Bielak LF, Peyser PA, Stegall MD (2005) Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant 5:1689–1693

    Article  PubMed  Google Scholar 

  32. Raggi P, Giachelli C, Bellasi A (2007) Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 4:26–33

    Article  CAS  PubMed  Google Scholar 

  33. Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233

    Article  CAS  PubMed  Google Scholar 

  34. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356–363

    Article  CAS  PubMed  Google Scholar 

  35. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U (2006) Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease–impact of calcium and vitamin D therapy. Nephrol Dial Transplant 21:1906–1914

    Article  CAS  PubMed  Google Scholar 

  36. Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German study group for growth hormone treatment in chronic renal failure. N Engl J Med 343:923–930

    Article  CAS  PubMed  Google Scholar 

  37. Rabkin R, Sun DF, Chen Y, Tan J, Schaefer F (2005) Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 20:313–318

    Article  PubMed  Google Scholar 

  38. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study was funded by a grant (FORUN-program) from the Medical Faculty, University of Rostock. The authors wish to thank Dorothea Gütschow and Katrin Sievert-Kuechenmeister for outstanding technical assistance.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Children’s Hospital Rostock, Ernst-Heydemann-Str. 8, 18057, Rostock, Germany

    Dagmar-Christiane Fischer, Claudia Jensen, Anja Rahn, Birgit Salewski & Dieter Haffner

  2. Institute for Biostatistics and Informatics in Medicine, University of Rostock, Rostock, Germany

    Günther Kundt

  3. Laboratory of Pathophysiology, Department of Medicine, University of Antwerp, Antwerp, Belgium

    Geert J. Behets & Patrick D’Haese

Authors
  1. Dagmar-Christiane Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anja Rahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Birgit Salewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Günther Kundt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Geert J. Behets
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick D’Haese
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dieter Haffner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dagmar-Christiane Fischer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fischer, DC., Jensen, C., Rahn, A. et al. Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol 26, 111–117 (2011). https://doi.org/10.1007/s00467-010-1660-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1660-5

Keywords

Search

Navigation